A doctor’s evidence-based explanation of the science, symptoms and pathways behind this topic.
Written by Dr Bikram Ratti MBBS (London) MRCGP
Private GP & Men’s Health Specialist
The Doctor’s Practice, Birmingham
Instagram: @thedoctorspractice | @drbikofficial | @drrinkuofficial
Introduction
In my work at The Doctor’s Practice in Edgbaston, Birmingham, weight loss medicine has changed more in the past few years than almost any other area of general practice.
First came the rise of injectable GLP-1 medicines. Then came increasing public awareness of treatments such as Wegovy® and Mounjaro®. Now, the UK has approved a new development: a once-daily Wegovy pill.
This is significant because, until now, the most effective modern weight-loss medicines have largely been injections. The new Wegovy tablet contains semaglutide, the same active ingredient used in Wegovy injections, but in an oral daily form.
For patients who are eligible, this may offer another option. For people who dislike needles or feel anxious about injections, it may feel like a major step forward. But it is important to understand what the Wegovy pill is — and what it is not.
It is not a cosmetic slimming tablet.
It is not a quick fix.
It is a prescription-only medicine for people living with obesity, or those who are overweight with weight-related health conditions, and it should be used alongside diet, physical activity and medical supervision.
The approval of the Wegovy pill marks an important moment in obesity medicine. It gives clinicians and patients a potential oral alternative to injectable GLP-1 treatment, but careful assessment remains essential. Eligibility, side effects, medical history, lifestyle support and long-term monitoring all matter.
The Science Behind the Wegovy Pill
The Wegovy pill contains semaglutide.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. GLP-1 is a hormone naturally released by the gut after eating. It helps regulate appetite, satiety and blood sugar control.
By mimicking GLP-1 activity, semaglutide can help people feel fuller, reduce appetite and support weight loss when combined with lifestyle changes.
The new oral Wegovy tablet is taken once daily. It is designed as an alternative to weekly injections for eligible adults living with obesity or overweight with weight-related health conditions.
This matters because medication format affects real-life adherence. Some patients are comfortable with injections. Others are not. A tablet may make treatment feel more accessible for certain people.
However, oral GLP-1 treatment also requires careful instructions. These medicines often need to be taken in a specific way to allow proper absorption.
How Is the Wegovy Pill Different from Wegovy Injections?
The active ingredient is the same: semaglutide.
The difference is the route of delivery.
Wegovy injections are given once weekly. The Wegovy pill is taken once daily.
That difference may sound simple, but it changes the patient experience. Some people prefer a weekly injection because it is less frequent. Others prefer tablets because they dislike needles.
The best option depends on the individual.
Important factors include:
• medical history
• BMI and weight-related risk
• previous medication tolerance
• lifestyle routine
• appetite pattern
• side effects
• patient preference
• long-term monitoring needs
This is why weight loss treatment should begin with proper medical assessment, not simply choosing the newest product.
Who May Be Eligible?
The UK approval is for adults living with obesity, usually defined as a BMI of 30 or above, or adults who are overweight with a BMI of 27 or above and have at least one weight-related health condition.
Weight-related conditions may include issues such as high blood pressure, abnormal cholesterol, prediabetes, type 2 diabetes, obstructive sleep apnoea or other metabolic risk factors.
Eligibility should always be assessed by a healthcare professional.
At The Doctor’s Practice, patients interested in medical weight management can be reviewed through our Weight Loss Injection Service, where we assess suitability, medical history, risks and ongoing monitoring.
Although the new medicine is a tablet rather than an injection, the same principle applies: prescription weight loss treatment should be medically supervised.
What Did the Research Show?
The UK approval was based on evidence from clinical trials of oral semaglutide.
In the OASIS 4 trial, semaglutide tablets were studied in adults with obesity or overweight with at least one weight-related condition, alongside diet and exercise support.
The trial reported clinically meaningful weight loss compared with placebo over 64 weeks. Importantly, all participants received lifestyle support, including advice on diet and physical activity.
This is a key point.
The Wegovy pill was not studied as a stand-alone shortcut. It was studied as part of a broader weight-management programme.
That is how obesity medicine should be practised.
Is the Wegovy Pill Available on the NHS?
At the time of writing, the Wegovy pill has been approved in the UK by the MHRA, but NHS funding and access will depend on NICE assessment and commissioning decisions.
This means initial access is expected to be through private prescription rather than routine NHS prescribing.
The existing NICE guidance for semaglutide relates to Wegovy for managing overweight and obesity in adults, alongside reduced-calorie diet and increased physical activity. The oral version will need to be considered within its own regulatory and access pathway.
Patients should be cautious about any online seller claiming immediate access without proper clinical checks.
GLP-1 medicines are prescription-only medicines. They should not be purchased from unregulated sources, beauty salons, social media sellers or websites offering treatment without a proper consultation.
Wegovy Pill vs Mounjaro: What Is the Difference?
This is one of the most common questions patients are likely to ask.
Wegovy contains semaglutide and acts on the GLP-1 receptor.
Mounjaro® contains tirzepatide and acts on both GLP-1 and GIP receptors.
Both medicines can support weight loss in appropriate patients, but they are not identical. They differ in mechanism, dosing, formulation, side-effect profile and clinical trial evidence.
Mounjaro is currently given by injection. The newly approved Wegovy pill is an oral semaglutide tablet.
For patients comparing options, the question should not simply be “which is strongest?” but “which is safest and most appropriate for me?”
That depends on medical history, weight-related risks, previous treatment experience, tolerability and long-term goals.
Patients with more complex metabolic concerns may benefit from a wider assessment through our Metabolic Clinic.
Possible Side Effects
Like injectable GLP-1 medicines, oral semaglutide can cause side effects.
The most common are gastrointestinal.
These may include:
• nausea
• vomiting
• diarrhoea
• constipation
• indigestion
• reduced appetite
For many patients, side effects are mild to moderate and improve over time, especially when medication is introduced gradually.
However, side effects should never be dismissed.
Some patients may not tolerate GLP-1 medication. Others may need dose adjustment, slower escalation or alternative treatment.
Patients should also be assessed for contraindications and cautions before starting treatment.
Why Medical Supervision Matters
Weight loss medicine is not just about prescribing a drug.
Good obesity care includes:
• baseline medical assessment
• blood pressure review
• metabolic risk assessment
• medication review
• discussion of side effects
• nutritional support
• muscle preservation strategy
• follow-up monitoring
• long-term weight maintenance planning
This is particularly important because rapid or significant weight loss can affect muscle mass, nutrition, gallbladder risk, energy levels and body composition.
At our clinic, some patients combine weight management with broader Health Screening to identify related issues such as cholesterol, diabetes risk, liver health, inflammation, thyroid function and vitamin deficiencies.
The goal should not be weight loss at any cost.
The goal should be healthier weight loss.
The Muscle Preservation Problem
One of the biggest concerns in modern weight-loss medicine is not simply how much weight someone loses, but what kind of weight they lose.
Weight loss can include fat mass, water and lean muscle.
For long-term health, preserving muscle is essential.
This is especially important for:
• adults over 40
• post-menopausal women
• men with low testosterone
• people with sedentary lifestyles
• patients losing weight rapidly
Protein intake, resistance training and medical monitoring all matter.
This is why weight-loss medication should sit within a structured plan rather than being treated as an isolated prescription.
Myths vs Facts
Myth: The Wegovy pill is just a slimming tablet.
Fact: It is a prescription-only GLP-1 medicine licensed for weight management in eligible patients.
Myth: Tablets are automatically safer than injections.
Fact: The route is different, but medical assessment and monitoring are still required.
Myth: The Wegovy pill replaces diet and exercise.
Fact: Clinical trials used the medicine alongside lifestyle support.
Myth: Anyone can take it privately.
Fact: Suitability depends on BMI, weight-related conditions, medical history and contraindications.
Myth: It is the same as Mounjaro.
Fact: Wegovy contains semaglutide. Mounjaro contains tirzepatide. They work differently.
Evidence-Based Weight Loss Support
The best results usually come from combining medical treatment with behavioural and metabolic support.
This may include:
• nutrition planning
• protein optimisation
• resistance training
• sleep improvement
• alcohol reduction
• metabolic monitoring
• medication review
• long-term maintenance planning
Patients who are unsure whether weight-loss medication is appropriate can begin with a Private GP consultation to review their health, risk factors and options.
Where medication is appropriate, ongoing follow-up is essential.
Where medication is not appropriate, there may still be meaningful strategies to improve metabolic health.
Assessment at The Doctor’s Practice
At The Doctor’s Practice — a private GP-led clinic in Edgbaston, Birmingham — we approach weight loss as a medical issue, not a cosmetic one.
Patients are assessed carefully, with attention to BMI, waist circumference, medical history, blood pressure, metabolic health, medications, lifestyle and long-term goals.
Where appropriate, we discuss evidence-based weight management options, including GLP-1 medicines, alongside nutrition, exercise and follow-up support.
The arrival of a Wegovy pill may offer patients another option, but the foundation remains the same: safe prescribing, proper monitoring and realistic long-term planning.
FAQs
What is the Wegovy pill?
The Wegovy pill is an oral form of semaglutide, a GLP-1 receptor agonist used for weight management in eligible adults.
Is the Wegovy pill approved in the UK?
Yes. The UK medicines regulator has approved the Wegovy pill for eligible adults living with obesity or overweight with a weight-related condition.
Is the Wegovy pill the same as Mounjaro?
No. Wegovy contains semaglutide. Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors.
Will the Wegovy pill be available on the NHS?
NHS availability will depend on NICE assessment and local commissioning decisions. Initial access is expected privately.
Is the Wegovy pill better than injections?
Not necessarily. Some patients may prefer tablets, while others may prefer weekly injections. The best option depends on medical suitability and patient preference.
Can I buy the Wegovy pill online?
GLP-1 medicines should only be obtained from legitimate pharmacies with a prescription issued after a proper consultation with a healthcare professional.
Where can I discuss weight loss treatment in Birmingham?
Patients seeking doctor-led weight loss support can attend The Doctor’s Practice in Edgbaston, Birmingham for assessment and personalised advice.
Personal Note
The approval of a Wegovy pill is an important moment in weight-loss medicine.
But the medicine is only part of the story.
Obesity is complex. Appetite, metabolism, hormones, sleep, stress, genetics and environment all interact.
The most effective care is rarely about simply starting a tablet or injection. It is about understanding the person in front of you, assessing risk properly and building a plan that can be sustained.
That is where doctor-led weight management matters.
Book an Appointment with Dr Bik
The Doctor’s Practice
7 Chad Square, Hawthorne Road
Edgbaston, Birmingham B15 3TQ
Website: https://www.thedoctorspractice.co.uk
Book: https://thedoctorspractice.co.uk/book-an-appointment/
Google Maps: https://share.google.com/X4VOVkY3Vz5Fgfj1C
Phone: 0121 661 2366
WhatsApp: +447388623527
Instagram: @thedoctorspractice | @drbikofficial | @drrinkuofficial
References
Novo Nordisk. Wegovy® pill becomes first daily GLP-1 weight-loss pill approved in the UK. 2026.
https://ml-eu.globenewswire.
Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025.
https://www.nejm.org/doi/10.
National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875.
https://www.nice.org.uk/
Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK. 2026.
https://www.gov.uk/government/
This article is intended for general educational purposes only and does not replace a personalised medical consultation. Individual symptoms, results and treatment options vary. For advice tailored to your health, please consult a qualified doctor.